GLP-1 Research Cycle Summary — May 22, 2026
This research cycle tracked major structural shifts in the GLP-1 and obesity treatment space across clinical, corporate, legal, and pricing dimensions.
Key Findings
-
Supreme Court Upholds Medicare Price Negotiations & Novo Nordisk Responds with 50% List Price Cuts On May 18, 2026, the U.S. Supreme Court rejected pharmaceutical appeals, clearing the legal path for Medicare negotiated prices. This cements the negotiated Maximum Fair Price (MFP) of $274 per month for semaglutide products (Ozempic, Rybelsus, Wegovy), set to take effect on January 1, 2027. In a defensive commercial move, Novo Nordisk announced it will slash U.S. list prices of Ozempic and Wegovy by up to 50% to a flat rate of $675 per month starting January 1, 2027, protecting commercial formulary access.
-
Eli Lilly's Foundayo (Orforglipron) FDA Approval and Launch Eli Lilly received FDA approval for Foundayo™ (orforglipron), its daily oral GLP-1 pill, on April 1, 2026, launching it via LillyDirect on April 6. Showing 12.4% weight loss at the highest dose, Foundayo holds a massive competitive advantage over Novo Nordisk's oral options because it can be taken any time of day without food or water restrictions. It is priced at $149/month for self-pay and $25/month with commercial insurance, with a Medicare Part D price of $50/month arriving July 1, 2026.
-
Novo Nordisk's Next-Gen CagriSema Fails Head-to-Head Trial vs. Zepbound On February 23, 2026, Novo Nordisk's next-gen obesity candidate, CagriSema, failed to meet non-inferiority or superiority against Eli Lilly's Zepbound in an 84-week Phase 3 trial (23.0% weight loss vs. 25.5% for Zepbound). The clinical failure knocked 15% off Novo's stock price, pushing it to a four-year low and reinforcing Lilly's dual-agonist market leadership.
-
Novo Nordisk's Wegovy Pill: FDA Approval and Rapid Market Adoption Approved on December 22, 2025, and launched in early January 2026, the once-daily Wegovy Pill (oral semaglutide 25mg) achieved 16.6% weight loss in the OASIS 4 trial. It is experiencing rapid physician uptake, with over 70% of surveyed primary care physicians and endocrinologists prescribing it in its first month, acting as a major market expander for injection-hesitant patients despite strict fasting requirements.
Open Threads for Future Cycles
- Retatrutide Osteoarthritis Pain Data: Analyze Lilly's multi-indication Phase 3 osteoarthritis pain data to quantify TAM expansion beyond obesity/diabetes.
- Neuropsychiatry & Addiction Applications: Investigate clinical trials evaluating Wegovy for heavy drinking/alcohol use disorder and NIH findings on GLP-1 hedonic eating suppression.